enVVeno Medical (NVNO) Projected to Post Earnings on Thursday

enVVeno Medical (NASDAQ:NVNO) is projected to issue its results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($4.69) per share and revenue of $1.00 million for the quarter.

enVVeno Medical (NASDAQ:NVNO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($5.89) EPS for the quarter, beating analysts’ consensus estimates of ($8.40) by $2.51. On average, analysts expect enVVeno Medical to post $-16 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

enVVeno Medical Stock Up 0.7%

Shares of NASDAQ NVNO opened at $10.46 on Tuesday. The stock has a market cap of $6.99 million, a P/E ratio of -0.41 and a beta of 1.09. The firm’s 50-day simple moving average is $10.71 and its 200 day simple moving average is $10.82. enVVeno Medical has a fifty-two week low of $8.67 and a fifty-two week high of $184.45.

Institutional Trading of enVVeno Medical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of enVVeno Medical in the second quarter worth about $51,000. Creative Planning purchased a new stake in shares of enVVeno Medical in the 2nd quarter valued at approximately $54,000. Geode Capital Management LLC boosted its stake in enVVeno Medical by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock worth $796,000 after purchasing an additional 2,211 shares during the period. Finally, Perceptive Advisors LLC purchased a new position in enVVeno Medical during the 2nd quarter worth approximately $5,127,000. Institutional investors and hedge funds own 34.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on NVNO shares. Weiss Ratings lowered shares of enVVeno Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. LADENBURG THALM/SH SH upgraded enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Finally, Zacks Research raised enVVeno Medical to a “hold” rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

enVVeno Medical Company Profile

enVVeno Medical, Inc is a clinical?stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long?term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low?profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.